
Immunocore bags US$75m in Series C round
The round included support from existing investors and funds and accounts managed by BlackRock. Immunocore said it will use the proceeds to ...

Roche Phase III study misses COVID-19 endpoint
In the Phase III REMDACTA trial, the Swiss pharma major combined its cytokine storm blocker tocolizumab with Gilead Science’s viral transcription...

Valneva in talks with EU about 60 million vaccine doses
VLA2001 is currently the only inactivated vaccine candidate in clinical trials against COVID-19 in Europe. The vaccine candidate entered Phase I/II...

Oxular Ltd raises US$37m
Oxford-based Oxular said it will use the proceeds to finance Phase II studies evaluatingO the company’s lead asset, OXU-001, for the treatment of...

LSP leads €21m round into Neurent Medical
Galway-based medical device company Neurent Medical, which is focussed on chronic inflammatory diseases of the sinuses and nasal passages said it...

V-Bio Ventures launches second fund at €78m
With the investment, the Belgian biotech sector gets a cash injection. According to V-Bio Ventures, the new fund will build on the investment...

Germany orders antibody therapies from USA
Although there is no centralised approval required for biologics from the European Medicines Agency, Germany's Health Minister Jens Spahn has...